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Introduction
Diabetes is a major risk factor for left ventricular dys-
function with cardiac and renal fibrosis. C-type natriure-
tic peptide (CNP) is a 22 amino-acid peptide produced
mainly in the cardiac endothelium with potent cardiac
unloading, anti-fibrotic and antihypertensive effects, but
minimal renal actions. Using this knowledge we designed
a natriuretic peptide CBA-NP by fusing a 6 AA sequence
(KVLRRH) from BNP to the C-terminus and a 5 AA
sequence (RMDRI) from ANP to the N-terminus of CNP
to enhance beneficial renal effects while maintaining
CNP’s inherent cardioprotective properties.
Hypothesis
Chronic treatment with CBA-NP will have direct anti-
fibrotic and humoral effects in a rat model of diabetic
cardiomyopathy.
Methods
Using three groups of six male Wistar rats, (normal
control, diabetic control, and diabetic treated with CBA-
NP) one dose of streptozotocin was administered to
induce diabetes. One month after induction of diabetes
ALZET pumps with 0.1μg/kg/min of CBA-NP or saline
were serially implanted subcutaneously every 14 days
over the course of 2 months. Cardiac function was
assessed by echocardiography. Neurohormones by RIA.
Fibrosis by picrosirius red staining. Ultrastructural fea-
tures by electron microscopy.
Results
CBA-NP treatment attenuated LV hypertrophy (0.24±.01
mg/g body weight) compared to diabetic control (0.26±.01)
and was comparable to the normal control (0.24±.01). LV
interstitial and perivascular fibrosis percentage was signifi-
cantly reduced in the CBA-NP treated group (3.27 to 1.80
and 3.87 to 1.77) as compared to the diabetic control. Ejec-
tion fraction (84.0± 1.2% vs. 78.0±1.7 %) and fractional
shortening (48±1.2% vs. 41±1%) were significantly
improved after CBA-NP treatment compared to diabetic
control. Kidney cortical and medullary percent fibrosis was
significantly reduced (4.58±0.80 to 2.16±0.14 and 4.43±0.6
to 1.23±0.3) after CBA-NP treatment as compared to the
untreated group. GFR significantly improved (1.74±0.18 to
2.42±0.18) with reduction in glomerular basement mem-
brane thickness. There was a significant decrease in plasma
renin, aldosterone and BNP, while plasma cGMP increased
in the treated group compared to the untreated group.
Conclusion
CBA-NP treatment attenuated LV hypertrophy, reduced
cardiac and renal fibrosis, and improved cardiac and
renal function with suppression of renin and aldoster-
one, suggesting a potential therapeutic benefit in dia-
betic cardiomyopathy.
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